[go: up one dir, main page]

IL205432A0 - Method of identigfying safe nmda receptor antagonists - Google Patents

Method of identigfying safe nmda receptor antagonists

Info

Publication number
IL205432A0
IL205432A0 IL205432A IL20543210A IL205432A0 IL 205432 A0 IL205432 A0 IL 205432A0 IL 205432 A IL205432 A IL 205432A IL 20543210 A IL20543210 A IL 20543210A IL 205432 A0 IL205432 A0 IL 205432A0
Authority
IL
Israel
Prior art keywords
identigfying
receptor antagonists
nmda receptor
safe
safe nmda
Prior art date
Application number
IL205432A
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of IL205432A0 publication Critical patent/IL205432A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2842Pain, e.g. neuropathic pain, psychogenic pain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2857Seizure disorders; Epilepsy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2871Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL205432A 2007-11-06 2010-04-29 Method of identigfying safe nmda receptor antagonists IL205432A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592207P 2007-11-06 2007-11-06
US98592407P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (1)

Publication Number Publication Date
IL205432A0 true IL205432A0 (en) 2010-12-30

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205432A IL205432A0 (en) 2007-11-06 2010-04-29 Method of identigfying safe nmda receptor antagonists

Country Status (12)

Country Link
EP (1) EP2212694A4 (es)
JP (1) JP2011503013A (es)
KR (1) KR20100100858A (es)
CN (1) CN101918832A (es)
AU (1) AU2008323877A1 (es)
BR (1) BRPI0820406A2 (es)
CA (1) CA2704475A1 (es)
EA (1) EA201070571A1 (es)
IL (1) IL205432A0 (es)
MX (1) MX2010004971A (es)
WO (1) WO2009061935A2 (es)
ZA (1) ZA201003724B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159960A (ja) * 2011-06-08 2014-09-04 Astellas Pharma Inc 慢性疼痛モデル動物における自発痛行動自動測定法
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-4-클로로키누레닌의 치료적 용도
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
CN111960514A (zh) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 一种用于脱硫废水浓缩的电渗析智能控制系统及方法
CN118019541A (zh) 2021-09-02 2024-05-10 埃默里大学 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
KR20030063765A (ko) * 2002-01-24 2003-07-31 엘지전자 주식회사 광픽업용 대물렌즈
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2005061536A1 (en) * 2003-12-16 2005-07-07 Aventis Pharmaceuticals Inc. Secreted neural apoptosis inhibiting proteins
EP1791569A4 (en) * 2004-08-23 2009-12-16 Univ Emory Improved selection of-ph dependent compounds for in vivo therapy

Also Published As

Publication number Publication date
MX2010004971A (es) 2010-07-28
EP2212694A2 (en) 2010-08-04
CN101918832A (zh) 2010-12-15
AU2008323877A1 (en) 2009-05-14
EP2212694A4 (en) 2011-10-12
JP2011503013A (ja) 2011-01-27
BRPI0820406A2 (pt) 2015-05-19
ZA201003724B (en) 2013-10-30
WO2009061935A3 (en) 2009-08-20
CA2704475A1 (en) 2009-05-14
KR20100100858A (ko) 2010-09-15
WO2009061935A2 (en) 2009-05-14
EA201070571A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
PT2129654E (pt) Antagonistas do receptor de glucagina
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
GB2456192B (en) Dust-separating apparatus
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
PL2927224T3 (pl) Antagoniści receptora
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
ZA201103156B (en) Isonicotinamide orexin receptor antagonists
EP2350024A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS
ZA201006587B (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
PL2799428T3 (pl) Antagoniści glukagonu
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
ZA201005341B (en) Methods for inhibiting angiogenesis using egfl8 antagonists
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
IL205432A0 (en) Method of identigfying safe nmda receptor antagonists
IL241743A0 (en) Non-competitive nicotinic receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
EP2367810A4 (en) CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS
IL211996A0 (en) Process for the preparation of substituted phenylalanines
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
EP2173695A4 (en) PROCESS FOR THE PREPARATION OF CIS-4-TERT.-BUTYLCYCLOHEXANOL